We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.33%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.83B
AUM Growth
-$147M
Cap. Flow
+$37.6M
Cap. Flow %
0.48%
Top 10 Hldgs %
76.26%
Holding
100
New
11
Increased
18
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$125M
2
INSM icon
Insmed
INSM
+$125M
3
ALKS icon
Alkermes
ALKS
+$103M
4
BCYC
Bicycle Therapeutics
BCYC
+$101M
5
ALMS
Alumis Inc
ALMS
+$20.8M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$308M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$55.5M
3
ROIV icon
Roivant Sciences
ROIV
+$50.6M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$38.2M
5
AKRO
Akero Therapeutics
AKRO
+$34.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LONA
51
LeonaBio Inc
LONA
$65.3M
$8.36M 0.11%
315,381
– –
VERV
52
DELISTED
Verve Therapeutics
VERV
$8.25M 0.11%
1,691,530
– –
RLAY icon
53
Relay Therapeutics
RLAY
$4B
$7.56M 0.1%
1,160,117
– –
MIRM icon
54
Mirum Pharmaceuticals
MIRM
$6.54B
$6.51M 0.08%
190,476
– –
TNGX icon
55
Tango Therapeutics
TNGX
$4.21B
$6.43M 0.08%
750,000
– –
KALA icon
56
KALA BIO
KALA
$12.9M
$6.32M 0.08%
17,827
+12,495
+234% +$4.13M
DBVT
57
DBV Technologies
DBVT
$814M
$5.85M 0.07%
1,461,426
– –
DSGN icon
58
Design Therapeutics
DSGN
$750M
$5.68M 0.07%
1,695,294
+33,174
+2% +$129K
CTNM
59
Contineum Therapeutics
CTNM
$539M
$5.5M 0.07%
+312,500
New +$5.03M
PRAX icon
60
Praxis Precision Medicines
PRAX
$8.11B
$5.44M 0.07%
131,533
– –
CRSP icon
61
CRISPR Therapeutics
CRSP
$4.69B
$5.4M 0.07%
+100,000
New +$5.78M
PRME icon
62
Prime Medicine
PRME
$549M
$5.29M 0.07%
1,028,466
– –
CNTA
63
DELISTED
Centessa Pharmaceuticals
CNTA
$4.96M 0.06%
+549,212
New +$5.21M
HOOK
64
DELISTED
HOOKIPA Pharma
HOOK
$4.81M 0.06%
812,815
– –
SGMT icon
65
Sagimet Biosciences
SGMT
$433M
$4.73M 0.06%
1,381,898
– –
CRNX icon
66
Crinetics Pharmaceuticals
CRNX
$8.88B
$4.65M 0.06%
+103,927
New +$4.8M
TLIS
67
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$4.4M 0.06%
508,323
– –
ALEC icon
68
Alector
ALEC
$168M
$4.21M 0.05%
+927,264
New +$4.77M
OPT
69
DELISTED
Opthea Limited American Depositary Shares
OPT
$4.2M 0.05%
2,173,622
-4,204
-0.2% -$13.3K
SKYE icon
70
Skye Bioscience
SKYE
$21.4M
$4M 0.05%
+500,000
New +$5.93M
PCVX icon
71
Vaxcyte
PCVX
$7.65B
$3.69M 0.05%
48,885
– –
ARCT icon
72
Arcturus Therapeutics
ARCT
$164M
$3.68M 0.05%
+151,329
New +$4.59M
GBIO
73
DELISTED
Generation Bio
GBIO
$3.4M 0.04%
120,696
+83,574
+225% +$2.72M
ELVN icon
74
Enliven Therapeutics
ELVN
$3.78B
$2.68M 0.03%
114,833
– –
CYPH
75
Cypherpunk Technologies Inc
CYPH
$63.4M
$2.3M 0.03%
1,172,175
– –
1 2
3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Baker Bros. Advisors held 100 positions worth $7.83B, down 1.8% from $7.97B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors's Q2 2024 filing shows 11 new, 18 increased, 11 reduced and 5 closed positions. Its largest new stake was Summit Therapeutics: 23,222,222 shares worth $181M. The largest sale was Incyte, an estimated $308M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2024 buy was Summit Therapeutics: 23,222,222 shares worth $181M.
  • Baker Bros. Advisors added most to Insmed in Q2 2024, an estimated $125M increase.
  • Baker Bros. Advisors's biggest Q2 2024 reduction was Incyte, cutting an estimated $308M.
  • Baker Bros. Advisors fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $3.23M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $7.83B portfolio in Q2 2024.
  • Baker Bros. Advisors opened 11 new positions and closed 5 in Q2 2024.
  • Baker Bros. Advisors's portfolio value fell 1.8% quarter-over-quarter to $7.83B.

Based on Baker Bros. Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.